

EMA/408654/2016

European Medicines Agency decision

P/0187/2016

of 15 July 2016

on the acceptance of a modification of an agreed paediatric investigation plan for landiolol (hydrochloride) (EMA-001150-PIP02-13-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0187/2016

of 15 July 2016

on the acceptance of a modification of an agreed paediatric investigation plan for landiolol (hydrochloride) (EMA-001150-PIP02-13-M01) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0283/2014 issued on 30 October 2014 ,

Having regard to the application submitted by AOP Orphan Pharmaceuticals AG on 3 March 2016 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 27 May 2016, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for landiolol (hydrochloride), powder for solution for infusion, concentrate for solution for injection, intravenous use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to AOP Orphan Pharmaceuticals AG, Wilhelminenstrasse 91/II f, A-1160 – Vienna, Austria.

Done at London, 15 July 2016

For the European Medicines Agency
Zaïde Frias
Head of Division
Human Medicines Research and Development Support
(Signature on file)

EMA/PDCO/180309/2016

London, 27 May 2016

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-001150-PIP02-13-M01

Scope of the application

Active substance(s):

Landiolol (hydrochloride)

Condition(s):

Treatment of supraventricular arrhythmias

Pharmaceutical form(s):

Powder for solution for infusion

Concentrate for solution for injection

Route(s) of administration:

Intravenous use

Name / corporate name of the PIP applicant:

AOP Orphan Pharmaceuticals AG

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, AOP Orphan Pharmaceuticals AG submitted to the European Medicines Agency on 3 March 2016 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0283/2014 issued on 30 October 2014.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 29 March 2016.

Scope of the modification

Some measures of the Paediatric Investigation Plan have been modified. Amendment of the scope of the Paediatric Investigation Plan to exclude the condition “Prevention of supraventricular arrhythmias”.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable.

2. Paediatric investigation plan

2.1. Condition

Treatment of supraventricular arrhythmias

2.1.1. Indication(s) targeted by the PIP

Treatment of supraventricular tachyarrhythmias

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Powder for solution for infusion

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	Study 1 Development of powder for solution suitable for paediatric use.
Non-clinical studies	0	Not applicable.
Clinical studies	1	Study 2 Multicentre open-label uncontrolled study to investigate the effectiveness and safety of landiolol in controlling supraventricular tachycardia including inappropriate sinus tachycardia, junctional ectopic tachycardia, atrial flutter, atrial fibrillation, focal atrial tachycardia; and atrioventricular nodal re-entry tachycardia and atrioventricular reciprocating (re-entry) tachycardia refractory to treatment with adenosine in surgical (peri- and postoperative, cardiac and non-cardiac surgery) and non- surgical paediatric patients.
Extrapolation, modelling and simulation studies	0	Not applicable.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By July 2018
Deferral for one or more measures contained in the paediatric investigation plan:	Yes